Analysts Set Integer Holdings Corporation (NYSE:ITGR) Price Target at $140.25

Key Points

• Integer Holdings Corporation has received a consensus rating of "Buy" from nine analysts, including one strong buy recommendation.
• The average 12-month price target among analysts for Integer is $140.25, reflecting some recent adjustments in price targets from various brokerages.
• The company reported earnings per share (EPS) of $1.55, slightly missing analysts' expectations, but revenue increased by 11.4% year-over-year, totaling $476 million.

Shares of Integer Holdings Corporation (NYSE:ITGR - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $140.25.

A number of research firms have weighed in on ITGR. Truist Financial cut their target price on shares of Integer from $145.00 to $137.00 and set a "buy" rating for the company in a research report on Friday, July 25th. Benchmark cut their target price on shares of Integer from $150.00 to $140.00 and set a "buy" rating for the company in a research report on Friday, April 25th. Wells Fargo & Company cut their target price on shares of Integer from $152.00 to $132.00 and set an "overweight" rating for the company in a research report on Friday, July 25th. Raymond James Financial cut their target price on shares of Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research report on Friday, July 25th. Finally, Wall Street Zen raised shares of Integer from a "sell" rating to a "hold" rating in a research report on Monday, May 19th.

Integer Stock Up 1.0%

Shares of NYSE:ITGR traded up $1.09 during trading on Friday, reaching $108.42. 177,116 shares of the company traded hands, compared to its average volume of 486,551. The firm has a fifty day simple moving average of $115.83 and a 200 day simple moving average of $120.96. The firm has a market cap of $3.80 billion, a P/E ratio of 47.76, a price-to-earnings-growth ratio of 0.83 and a beta of 1.02. Integer has a 1-year low of $104.93 and a 1-year high of $146.36. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a net margin of 4.61% and a return on equity of 12.27%. The business had revenue of $476.00 million during the quarter, compared to analyst estimates of $464.37 million. During the same period in the previous year, the firm posted $1.30 EPS. The firm's revenue for the quarter was up 11.4% on a year-over-year basis. Analysts anticipate that Integer will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Integer

In related news, Director Martin C. Maxwell sold 8,720 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $120.56, for a total value of $1,051,283.20. Following the sale, the director owned 22,170 shares of the company's stock, valued at $2,672,815.20. The trade was a 28.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Donald J. Spence sold 14,739 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the sale, the director directly owned 18,781 shares in the company, valued at approximately $2,260,856.78. The trade was a 43.97% decrease in their position. The disclosure for this sale can be found here. 2.16% of the stock is currently owned by corporate insiders.

Institutional Trading of Integer

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new stake in Integer during the fourth quarter worth about $38,073,000. Vaughan Nelson Investment Management L.P. bought a new stake in Integer during the first quarter worth about $33,337,000. Capital Research Global Investors grew its stake in Integer by 16.0% during the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider's stock worth $186,960,000 after buying an additional 194,895 shares during the last quarter. Nuveen LLC bought a new stake in Integer during the first quarter worth about $17,634,000. Finally, Millennium Management LLC grew its stake in Integer by 2,408.8% during the first quarter. Millennium Management LLC now owns 123,132 shares of the medical equipment provider's stock worth $14,531,000 after buying an additional 118,224 shares during the last quarter. Institutional investors own 99.29% of the company's stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.